In 2003, an international working group last reported on recommendations for diagnosis, response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that time, considerable progress has been made in elucidating the molecular pathogenesis of the disease that has resulted in the identification of new diagnostic and prognostic markers. Furthermore, therapies are now being developed that target disease-associated molecular defects. Recent developments prompted an international expert panel to provide updated evidence- and expert opinion-based recommendations for the diagnosis and management of AML, that contain both minimal requirements for general practice as well as standards for clinical trials. A new standardized reporting system for correlation of cytogenetic and molecular genetic data with clinical data is proposed.
ContributorsDohner, H. Estey, E. H. Amadori, S. Appelbaum, F. R. Buchner, T. Burnett, A. K. Dombret, H. Fenaux, P. Grimwade, D. Larson, R. A. Lo-Coco, F. Naoe, T. Niederwieser, D. Ossenkoppele, G. J. Sanz, M. A. Sierra, J. Tallman, M. S. Lowenberg, B. Bloomfield, C. D. European, LeukemiaNet
Disease Category: Cancer
Disease Name: Leukemia (acute myeloid)
Age Range: 18 - 100
Sex: Either
Nature of Intervention: Not specified
- Clinical experts
- Researchers
- Definition
- Literature review
- Semi structured discussion